(ACTU) Actuate Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock •

ACTU: Cancer, Injection, Inhibitor

Actuate Therapeutics, Inc. (NASDAQ:ACTU) is a clinical-stage biopharmaceutical company specializing in the development of innovative cancer therapies. Its lead product candidate, Elraglusib Injection, is a glycogen synthase kinase-3 (GSK-3) inhibitor designed to target metastatic pancreatic ductal adenocarcinoma (PDAC). The company is also investigating Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. Formerly known as Apotheca Therapeutics, Inc., the company rebranded as Actuate Therapeutics, Inc. in October 2015. Headquartered in Fort Worth, Texas, Actuate Therapeutics was incorporated in 2015 and is focused on advancing its pipeline of precision oncology therapies.

The companys approach centers on leveraging its expertise in kinase inhibition to develop targeted therapies that address unmet medical needs in oncology. Elraglusib, its flagship candidate, has shown potential in preclinical and early clinical studies to inhibit tumor growth and enhance anti-tumor immunity. Actuate Therapeutics is committed to advancing Elraglusib through clinical development, with a focus on improving outcomes for patients with aggressive and hard-to-treat cancers.

Based on and , Actuate Therapeutics, Inc. (NASDAQ:ACTU) is expected to experience the following trends over the next three months: - Technical Outlook: The stocks short-term moving averages (SMA 20: 7.84, SMA 50: 8.23) suggest potential resistance levels above the current price of 7.02. The ATR of 0.83 indicates moderate volatility, with price fluctuations likely remaining contained. - Fundamental Outlook: With a market cap of 152.89M USD, the company is positioned as a small-cap biotech firm. The lack of P/E and P/B ratios reflects its pre-profitability stage, which is common for clinical-stage biotechs. The focus will remain on clinical trial progress and pipeline advancements. - Expected Price Movement: The stock may face headwinds near the SMA 50 level (8.23). However, positive clinical updates or partnerships could drive upside momentum. Support is likely near the SMA 200 level (8.16).

Additional Sources for ACTU Stock

ACTU Stock Overview

Market Cap in USD 153m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception 2024-08-13

ACTU Stock Ratings

Growth 5y -21.2%
Fundamental -28.1%
Dividend 0.0%
Rel. Strength Industry -6.32
Analysts -
Fair Price Momentum 6.44 USD
Fair Price DCF -

ACTU Dividends

No Dividends Paid

ACTU Growth Ratios

Growth Correlation 3m -34%
Growth Correlation 12m -2.2%
Growth Correlation 5y -2.2%
CAGR 5y -15.80%
CAGR/Max DD 5y -0.39
Sharpe Ratio 12m -0.63
Alpha -27.08
Beta 1.09
Volatility 75.34%
Current Volume 16.9k
Average Volume 20d 22.2k
What is the price of ACTU stocks?
As of March 16, 2025, the stock is trading at USD 7.25 with a total of 16,939 shares traded.
Over the past week, the price has changed by +4.32%, over one month by -6.57%, over three months by -16.57% and over the past year by -15.80%.
Is Actuate Therapeutics a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Actuate Therapeutics (NASDAQ:ACTU) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -28.14 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ACTU as of March 2025 is 6.44. This means that ACTU is currently overvalued and has a potential downside of -11.17%.
Is ACTU a buy, sell or hold?
Actuate Therapeutics has no consensus analysts rating.
What are the forecast for ACTU stock price target?
According to ValueRays Forecast Model, ACTU Actuate Therapeutics will be worth about 7.2 in March 2026. The stock is currently trading at 7.25. This means that the stock has a potential downside of -0.14%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 7.2 -0.1%